Revenue from Contracts with Customers Schedule of Disaggregated Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 125,568,000	$ 106,732,000	$ 114,905,000
Instruments
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	31,074,000	21,441,000	20,839,000
Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	51,591,000	43,847,000	38,311,000
In Vitro Diagnostic Kits
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	9,413,000	9,445,000	6,745,000
Total product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	92,078,000	74,733,000	65,895,000
Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	11,636,000	8,790,000	6,115,000
Total product and service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	103,714,000	83,523,000	72,010,000
Collaboration
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	21,854,000	23,209,000	42,895,000
Americas
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	86,139,000	74,137,000	86,099,000
Americas | Instruments
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	18,578,000	12,033,000	10,556,000
Americas | Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	35,461,000	29,653,000	25,583,000
Americas | In Vitro Diagnostic Kits
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	2,522,000	3,014,000	2,473,000
Americas | Total product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	56,561,000	44,700,000	38,612,000
Americas | Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	7,724,000	6,228,000	4,592,000
Americas | Total product and service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	64,285,000	50,928,000	43,204,000
Americas | Collaboration
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	21,854,000	23,209,000	42,895,000
Europe and Middle East
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	30,289,000	25,715,000	21,791,000
Europe and Middle East | Instruments
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	8,083,000	6,677,000	6,561,000
Europe and Middle East | Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	12,484,000	10,847,000	9,934,000
Europe and Middle East | In Vitro Diagnostic Kits
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	6,601,000	6,094,000	3,982,000
Europe and Middle East | Total product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	27,168,000	23,618,000	20,477,000
Europe and Middle East | Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	3,121,000	2,097,000	1,314,000
Europe and Middle East | Total product and service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	30,289,000	25,715,000	21,791,000
Europe and Middle East | Collaboration
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	0	0	0
Asia Pacific
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	9,140,000	6,880,000	7,015,000
Asia Pacific | Instruments
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	4,413,000	2,731,000	3,722,000
Asia Pacific | Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	3,646,000	3,347,000	2,794,000
Asia Pacific | In Vitro Diagnostic Kits
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	290,000	337,000	290,000
Asia Pacific | Total product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	8,349,000	6,415,000	6,806,000
Asia Pacific | Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	791,000	465,000	209,000
Asia Pacific | Total product and service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	9,140,000	6,880,000	7,015,000
Asia Pacific | Collaboration
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 0	$ 0	$ 0